{"id":"dtg-3tc","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL4175547","moleculeType":"Small molecule","molecularWeight":"243.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dolutegravir prevents HIV integrase from inserting viral DNA into the host genome, while lamivudine inhibits reverse transcriptase to prevent conversion of viral RNA to DNA. Together, they provide complementary antiretroviral activity against HIV-1 and HIV-2, reducing viral load and allowing immune reconstitution.","oneSentence":"DTG/3TC is a fixed-dose combination of dolutegravir (an integrase strand transfer inhibitor) and lamivudine (a nucleoside reverse transcriptase inhibitor) that blocks HIV replication by inhibiting two key viral enzymes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:51.049Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced adults"},{"name":"HIV-1 infection in adolescents and children (weight-based formulations)"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT05373758","phase":"NA","title":"A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-02-07","conditions":"HIV Infections, AIDS, Virologic Failure","enrollment":648},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT07202546","phase":"PHASE2","title":"A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2026-02-11","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT05917509","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-07-06","conditions":"HIV Infections","enrollment":171},{"nctId":"NCT07001319","phase":"PHASE1","title":"Study of GS-3242 in Participants With HIV-1; Substudy-05","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-05-29","conditions":"HIV-1-infection","enrollment":30},{"nctId":"NCT04337450","phase":"PHASE2, PHASE3","title":"DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"PENTA Foundation","startDate":"2022-04-22","conditions":"HIV Infections","enrollment":386},{"nctId":"NCT05393193","phase":"PHASE4","title":"POC HIV Testing and Early DTG Use for Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2022-07-04","conditions":"HIV","enrollment":900},{"nctId":"NCT05630638","phase":"PHASE4","title":"Doravirine Dose Optimisation in Pregnancy","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2023-10-10","conditions":"HIV","enrollment":76},{"nctId":"NCT06061536","phase":"PHASE2","title":"Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.","status":"COMPLETED","sponsor":"Shanxi Kangbao Biological Product Co., Ltd.","startDate":"2023-11-02","conditions":"HIV","enrollment":64},{"nctId":"NCT07393659","phase":"PHASE3","title":"A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment","status":"NOT_YET_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2026-05-08","conditions":"HIV Infections","enrollment":183},{"nctId":"NCT03016533","phase":"PHASE3","title":"Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2017-06-06","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT06203132","phase":"PHASE3","title":"DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-01-27","conditions":"HIV-1-infection","enrollment":610},{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT05122767","phase":"PHASE1, PHASE2","title":"Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2023-05-24","conditions":"Tuberculosis, HIV","enrollment":92},{"nctId":"NCT03682848","phase":"PHASE3","title":"Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-05-06","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT05630872","phase":"PHASE2","title":"Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-02-13","conditions":"HIV-associated Tuberculosis","enrollment":30},{"nctId":"NCT05979311","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-02-09","conditions":"HIV, HIV Infections","enrollment":473},{"nctId":"NCT05911360","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-01-31","conditions":"HIV, HIV Infections","enrollment":205},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT07115368","phase":"PHASE1","title":"Study of GS-1219 in Participants With HIV-1","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2025-08-11","conditions":"HIV-1-infection","enrollment":4},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT04734652","phase":"PHASE2","title":"INSTI's For The Management of HIV-associated TB","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2022-02-18","conditions":"HIV/AIDS, Tuberculosis, Pulmonary","enrollment":122},{"nctId":"NCT03360682","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2018-04-13","conditions":"HIV-1-infection, Solid Organ Transplant","enrollment":19},{"nctId":"NCT06393387","phase":"","title":"Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States","status":"COMPLETED","sponsor":"Midway Specialty Care Center","startDate":"2024-06-01","conditions":"Hiv, HIV-1-infection, HIV Infections","enrollment":800},{"nctId":"NCT06497465","phase":"PHASE3","title":"Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-09-18","conditions":"Tuberculosis, HIV","enrollment":150},{"nctId":"NCT06967753","phase":"PHASE4","title":"Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)","status":"RECRUITING","sponsor":"UBATEC","startDate":"2025-07-31","conditions":"HIV, HIV-1","enrollment":50},{"nctId":"NCT06005610","phase":"PHASE2","title":"Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-01-04","conditions":"HIV I Infection","enrollment":93},{"nctId":"NCT06444620","phase":"PHASE3","title":"B/F/TAF to DTG/3TC Switch Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Nairobi","startDate":"2024-07-22","conditions":"HIV-1-infection","enrollment":240},{"nctId":"NCT02245022","phase":"PHASE2, PHASE3","title":"Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2017-03-14","conditions":"HIV, Pregnancy","enrollment":60},{"nctId":"NCT07138144","phase":"PHASE4","title":"Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up","status":"RECRUITING","sponsor":"José Antonio Mata Marín","startDate":"2025-07-12","conditions":"HIV Infections","enrollment":156},{"nctId":"NCT03754803","phase":"","title":"Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-11-08","conditions":"HIV Infections","enrollment":376},{"nctId":"NCT04453436","phase":"","title":"HIV Drug Resistance Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in Brazil","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2023-09-01","conditions":"HIV, Drug, Resistance","enrollment":2500},{"nctId":"NCT04880395","phase":"PHASE4","title":"Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3","status":"COMPLETED","sponsor":"Fundación Huésped","startDate":"2021-05-17","conditions":"HIV-1-infection","enrollment":265},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT02284035","phase":"PHASE3","title":"Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2015-09-27","conditions":"AIDS","enrollment":75},{"nctId":"NCT05549180","phase":"PHASE4","title":"Phase IV, a Clinical Trial to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2022-10-06","conditions":"HIV Infections","enrollment":84},{"nctId":"NCT04884139","phase":"PHASE4","title":"DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV:","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2021-07-14","conditions":"HIV-1-infection","enrollment":554},{"nctId":"NCT05729568","phase":"PHASE2","title":"A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-15","conditions":"HIV Infection","enrollment":83},{"nctId":"NCT05193994","phase":"PHASE3","title":"Triumeq in Amyotrophic Lateral Sclerosis","status":"TERMINATED","sponsor":"Macquarie University, Australia","startDate":"2022-02-24","conditions":"Amyotrophic Lateral Sclerosis","enrollment":419},{"nctId":"NCT07031063","phase":"PHASE4","title":"Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-04-01","conditions":"HIV Infection, Metabolic Syndrome, Antiretroviral Treatment","enrollment":124},{"nctId":"NCT06640192","phase":"PHASE2","title":"Administration of High Doses of Antiretroviral Drugs to Eliminate the Latent HIV-1 Reservoir","status":"RECRUITING","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2025-05-30","conditions":"HIV-1-infection","enrollment":24},{"nctId":"NCT06774872","phase":"PHASE2","title":"Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully","status":"RECRUITING","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2025-04-30","conditions":"HIV-1-infection","enrollment":408},{"nctId":"NCT06658977","phase":"PHASE3","title":"RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial","status":"TERMINATED","sponsor":"Macquarie University, Australia","startDate":"2024-11-15","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":12},{"nctId":"NCT00796263","phase":"PHASE3","title":"Antiretroviral Therapy for Acute and Chronic HIV Infection","status":"RECRUITING","sponsor":"SEARCH Research Foundation","startDate":"2009-05-13","conditions":"Acute HIV Infection, Chronic HIV Infection","enrollment":900},{"nctId":"NCT05585307","phase":"PHASE1","title":"Study of Novel Antiretrovirals in Participants With HIV-1","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2022-10-26","conditions":"HIV-1-infection","enrollment":49},{"nctId":"NCT06928090","phase":"","title":"Efficacy and Safety of DTG/3TC in Treatment-naïve HIV-1 Infected Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Chungnam National University Hospital","startDate":"2025-01-24","conditions":"HIV","enrollment":200},{"nctId":"NCT05924438","phase":"PHASE3","title":"A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Professor Francois Venter","startDate":"2023-11-08","conditions":"HIV-1-infection","enrollment":600},{"nctId":"NCT04034862","phase":"PHASE3","title":"Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs","status":"COMPLETED","sponsor":"University of Liege","startDate":"2019-10-01","conditions":"HIV Infections","enrollment":36},{"nctId":"NCT04880785","phase":"PHASE2","title":"Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2021-07-28","conditions":"HIV Infections","enrollment":121},{"nctId":"NCT04862975","phase":"","title":"Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-01-09","conditions":"Lactating Women on Select DOI, Breastmilk Fed Infants of Mothers on Select DOI, HIV Infections","enrollment":164},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT04012931","phase":"PHASE2","title":"A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-07-18","conditions":"HIV","enrollment":26},{"nctId":"NCT04019873","phase":"","title":"'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-11-18","conditions":"HIV Infections","enrollment":774},{"nctId":"NCT05477407","phase":"NA","title":"Adipose Tissue After Switch to Doravirine","status":"COMPLETED","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2022-10-06","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT03675815","phase":"PHASE4","title":"Body Composition Sub-study of the D2EFT Trial","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2019-12-05","conditions":"HIV Infections","enrollment":155},{"nctId":"NCT04707326","phase":"","title":"Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2019-11-01","conditions":"Hiv","enrollment":2040},{"nctId":"NCT05289986","phase":"PHASE4","title":"The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients","status":"TERMINATED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2023-11-21","conditions":"Hiv","enrollment":18},{"nctId":"NCT06037564","phase":"PHASE4","title":"B-free Multistage Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-13","conditions":"HIV, Drug Resistance, Drug Drug Interaction","enrollment":210},{"nctId":"NCT04585737","phase":"PHASE4","title":"Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF","status":"COMPLETED","sponsor":"Charlotte-Paige Rolle, MD","startDate":"2020-10-05","conditions":"HIV I Infection","enrollment":222},{"nctId":"NCT06637813","phase":"","title":"Establishment of a Database of HIV Subjects Initiating or Simplifying Dual Therapy With Dolutegravir/Lamivudine","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-10-30","conditions":"HIV -1 Infection","enrollment":1220},{"nctId":"NCT04871113","phase":"PHASE2","title":"A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2021-06-22","conditions":"HIV Infections","enrollment":62},{"nctId":"NCT06629480","phase":"NA","title":"Incidence of Metabolic Syndrome in People Living With HIV Without ExperienCe to ART Who Start DoLutegravir Based-Regimen Compared With BictegrAvir Based-RegimeN","status":"COMPLETED","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2021-06-25","conditions":"Antiretroviral Treatment, HIV Infection, Metabolic Cardiovascular Syndrome","enrollment":378},{"nctId":"NCT04076423","phase":"PHASE4","title":"A Phase IV Study to Assess the Impact of the Change of Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With HIV Infection","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2019-10-10","conditions":"HIV Infections","enrollment":141},{"nctId":"NCT03991013","phase":"PHASE2","title":"Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2019-08-08","conditions":"HIV Infections","enrollment":192},{"nctId":"NCT06619288","phase":"","title":"Good-first: B/F/TAF As First-line ART","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2024-07-01","conditions":"HIV Infection","enrollment":630},{"nctId":"NCT05546242","phase":"PHASE3","title":"Improving HIV-1 Control in Africa with Long Acting Antiretrovirals","status":"ACTIVE_NOT_RECRUITING","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2022-12-08","conditions":"HIV-1-infection","enrollment":540},{"nctId":"NCT06602622","phase":"PHASE4","title":"Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2024-08-14","conditions":"HIV, HIV Associate Weight Loss, HIV-1 Infection","enrollment":108},{"nctId":"NCT06580873","phase":"PHASE4","title":"Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)","status":"NOT_YET_RECRUITING","sponsor":"Saskatchewan Health Authority - Regina Area","startDate":"2024-09-30","conditions":"HIV-1-infection, Opioid Use Disorder","enrollment":40},{"nctId":"NCT03851588","phase":"PHASE2","title":"Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2019-12-19","conditions":"HIV Infections, Tuberculosis","enrollment":108},{"nctId":"NCT04002323","phase":"","title":"Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients","status":"COMPLETED","sponsor":"University Hospital Virgen de las Nieves","startDate":"2019-05-07","conditions":"HIV-1-infection","enrollment":88},{"nctId":"NCT06485154","phase":"PHASE4","title":"Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Witwatersrand, South Africa","startDate":"2024-06-01","conditions":"HIV Prevention","enrollment":100},{"nctId":"NCT04493216","phase":"PHASE2","title":"A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2020-11-18","conditions":"HIV Infections","enrollment":161},{"nctId":"NCT04904406","phase":"PHASE4","title":"Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals","status":"COMPLETED","sponsor":"Thomas Benfield","startDate":"2020-10-22","conditions":"Hiv, HIV Infections, HIV Cardiomyopathy","enrollment":81},{"nctId":"NCT02659761","phase":"PHASE4","title":"Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs","status":"TERMINATED","sponsor":"University College Dublin","startDate":"2016-11","conditions":"Human Immunodeficiency Virus","enrollment":33},{"nctId":"NCT05154747","phase":"PHASE3","title":"Long-Acting Treatment in Adolescents (LATA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2023-06-22","conditions":"Hiv, HIV Infections, HIV-1-infection","enrollment":476},{"nctId":"NCT04553081","phase":"PHASE4","title":"2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2020-05-26","conditions":"HIV-1-infection","enrollment":134},{"nctId":"NCT04549467","phase":"PHASE4","title":"Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test","status":"COMPLETED","sponsor":"Fundacion IDEAA","startDate":"2020-11-17","conditions":"Hiv, HIV-1-infection","enrollment":244},{"nctId":"NCT01910402","phase":"PHASE3","title":"A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2013-08-22","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":499},{"nctId":"NCT04900038","phase":"PHASE2","title":"A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2021-08-18","conditions":"HIV Infections","enrollment":85},{"nctId":"NCT01837277","phase":"PHASE2, PHASE3","title":"Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients","status":"COMPLETED","sponsor":"Fundação Bahiana de Infectologia","startDate":"2017-12-15","conditions":"Severely Immunocompromised HIV Patients","enrollment":186},{"nctId":"NCT02831764","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-07-18","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":722},{"nctId":"NCT02486133","phase":"PHASE3","title":"Dual Therapy With Boosted Darunavir + Dolutegravir","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-07","conditions":"HIV-Infection","enrollment":269},{"nctId":"NCT04638686","phase":"","title":"REal-Life Cohort With DOlutegravir + LAmivudina","status":"COMPLETED","sponsor":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","startDate":"2020-06-15","conditions":"HIV-1-infection","enrollment":185},{"nctId":"NCT04021290","phase":"PHASE3","title":"Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-11-11","conditions":"HIV Infections","enrollment":493},{"nctId":"NCT04826562","phase":"PHASE4","title":"Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)","status":"UNKNOWN","sponsor":"Saint Michael's Medical Center","startDate":"2021-09-26","conditions":"Human Immunodeficiency Virus","enrollment":40},{"nctId":"NCT04808973","phase":"PHASE3","title":"DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection in Pregnant Women","status":"COMPLETED","sponsor":"Fundação Bahiana de Infectologia","startDate":"2021-07-01","conditions":"HIV Infections, Pregnancy Related, Mother to Child Transmission","enrollment":20},{"nctId":"NCT05735535","phase":"PHASE3","title":"Women in Dual With Dolutegravir","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-10-01","conditions":"HIV Infections","enrollment":290},{"nctId":"NCT04022967","phase":"PHASE3","title":"ANRS 12372 MODERATO Study","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-09-21","conditions":"HIV-1-infection","enrollment":480},{"nctId":"NCT02831673","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-07-21","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":719},{"nctId":"NCT04050449","phase":"","title":"Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2019-10-28","conditions":"HIV-1-infection","enrollment":1339},{"nctId":"NCT04433780","phase":"PHASE3","title":"DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2021-01-04","conditions":"HIV-1-infection","enrollment":133},{"nctId":"NCT04340388","phase":"PHASE4","title":"Contribution of Dolutegravir to Obesity and Cardiovascular Disease","status":"COMPLETED","sponsor":"Augusta University","startDate":"2020-09-17","conditions":"HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases","enrollment":10},{"nctId":"NCT03446573","phase":"PHASE3","title":"Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-01-18","conditions":"HIV Infections","enrollment":743},{"nctId":"NCT03760458","phase":"PHASE1, PHASE2","title":"The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-09-09","conditions":"HIV Infections","enrollment":57},{"nctId":"NCT04827134","phase":"PHASE1","title":"A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2021-05-07","conditions":"HIV Infections","enrollment":33},{"nctId":"NCT03017872","phase":"PHASE4","title":"Dolutegravir and Darunavir Evaluation in Adults Failing Therapy","status":"UNKNOWN","sponsor":"Kirby Institute","startDate":"2017-11-23","conditions":"HIV Infections","enrollment":831},{"nctId":"NCT03916328","phase":"PHASE4","title":"BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study","status":"UNKNOWN","sponsor":"MU-JHU CARE","startDate":"2019-12-03","conditions":"Bone Loss","enrollment":330},{"nctId":"NCT02227238","phase":"PHASE3","title":"Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-12-11","conditions":"HIV Infections","enrollment":627}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":178,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avridela","Dual therapy","Dovato"],"phase":"marketed","status":"active","brandName":"DTG/3TC","genericName":"DTG/3TC","companyName":"University of Nairobi","companyId":"university-of-nairobi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DTG/3TC is a fixed-dose combination of dolutegravir (an integrase strand transfer inhibitor) and lamivudine (a nucleoside reverse transcriptase inhibitor) that blocks HIV replication by inhibiting two key viral enzymes. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based formulations).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}